ALPN Stock Overview
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Alpine Immune Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.63 |
| 52 Week High | US$10.30 |
| 52 Week Low | US$4.82 |
| Beta | 1.31 |
| 1 Month Change | 3.81% |
| 3 Month Change | 25.49% |
| 1 Year Change | -10.24% |
| 3 Year Change | 159.52% |
| 5 Year Change | -26.42% |
| Change since IPO | -20.10% |
Recent News & Updates
Recent updates
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right
Jun 03Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 29How Many Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Did Insiders Buy, In The Last Year?
Mar 03The Alpine Immune Sciences (NASDAQ:ALPN) Share Price Is Up 316% And Shareholders Are Delighted
Feb 05What Kind Of Shareholders Own Alpine Immune Sciences, Inc. (NASDAQ:ALPN)?
Jan 10
Does Alpine Immune Sciences (NASDAQ:ALPN) Have A Healthy Balance Sheet?
Dec 15Robert Conway Is The Independent Director of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) And They Just Picked Up 67% More Shares
Nov 24Shareholder Returns
| ALPN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.2% | 0.8% | 2.8% |
| 1Y | -10.2% | 7.1% | -9.2% |
Return vs Industry: ALPN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ALPN matched the US Market which returned -9.2% over the past year.
Price Volatility
| ALPN volatility | |
|---|---|
| ALPN Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ALPN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 85 | Mitch Gold | https://www.alpineimmunesciences.com |
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.
Alpine Immune Sciences, Inc. Fundamentals Summary
| ALPN fundamental statistics | |
|---|---|
| Market Cap | US$350.33m |
| Earnings (TTM) | -US$54.06m |
| Revenue (TTM) | US$31.82m |
11.0x
P/S Ratio-6.5x
P/E RatioIs ALPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPN income statement (TTM) | |
|---|---|
| Revenue | US$31.82m |
| Cost of Revenue | US$66.85m |
| Gross Profit | -US$35.03m |
| Other Expenses | US$19.03m |
| Earnings | -US$54.06m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | -110.10% |
| Net Profit Margin | -169.92% |
| Debt/Equity Ratio | 2.5% |
How did ALPN perform over the long term?
See historical performance and comparison